세계의 차세대 면역 치료 시장 보고서(2025년)

Next Generation Immunotherapies Global Market Report 2025

US $ 4,490 ￦ 6,319,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,490 ￦ 9,134,000

PDF (Site License)

PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,490 ￦ 11,949,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

차세대 면역 치료 시장 규모는 향후 몇 년 동안 급성장할 것으로 예상됩니다. 예측 기간 동안의 성장은 암 유병률 증가, 의료비 지출 증가, 키메라 항원 수용체(CAR) T세포 치료의 채택 증가, 만성 질환의 부담 증가, 차세대 약물 연구 확대에 기인할 수 있습니다. 예측 기간의 주요 트렌드에는 병용 치료으로의 전환, 기술 발전, 치료 접근법의 혁신, 개인 맞춤형 의학의 발전, 규제 지원 강화 등이 포함됩니다.

암 유병률의 증가는 차세대 면역 치료 시장의 확대를 견인할 것으로 예상됩니다. 암은 신체 내에서 비정상적인 세포의 통제되지 않은 성장과 확산을 특징으로 하는 질병 그룹입니다. 인구 고령화, 라이프스타일 변화, 환경 노출, 검출 방법의 발전 등 여러 가지 요인이 암 발생률 증가에 영향을 미칩니다. 차세대 면역 치료은 암에 대한 신체의 면역 반응을 강화하는 첨단 표적 치료법으로 효과와 지속성, 개인 맞춤화를 개선합니다. 예를 들어, 2024년 5월 미국 정부 기관인 국립암연구소(NCI)는 2022년에 전 세계적으로 약 2,000만 건의 신규 암 발병과 970만 건의 암 관련 사망이 발생했다고 보고했습니다. 2040년에는 2,990만 건의 신규 암 발병과 1,530만 건의 암 관련 사망이 예상됩니다. 따라서 암 유병률의 증가는 차세대 면역 치료 시장의 성장을 촉진하고 있습니다.

차세대 면역 치료제 시장을 선도하는 기업들은 암, 자가면역질환, 감염성 질환을 해결하기 위해 CAR T세포 치료와 같은 혁신적인 치료법 개발에 집중하고 있습니다. CAR T 세포 치료는 환자의 T 세포(면역 세포의 일종)가 키메라 항원 수용체(CAR)를 발현하도록 유전적으로 조작된 첨단 면역 치료 기술입니다. 예를 들어, 2025년 1월 인도의 세포 및 유전자 치료 스타트업인 Immuneel Therapeutics Private Limited는 인도 최초의 CAR T세포 치료제인 Qartemi를 출시했습니다. 이 치료제는 암세포를 인식하고 제거하도록 환자의 면역 세포를 유전적으로 변형하여 성인 B세포 비호지킨 림프종을 표적으로 하며, 매우 효과적이고 개인화된 접근 방식을 제공합니다. 기존 치료법에 반응하지 않는 환자들에게 새로운 희망을 제시하며, 유사한 국제적 옵션보다 비용 효율적이라는 추가적인 이점이 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나 바이러스 감염의 영향과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

• 세계의 차세대 면역 치료 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
• 최종 이용 산업의 분석
• 세계의 차세대 면역 치료 시장 : 성장률 분석
• 세계의 차세대 면역 치료 시장 실적 : 규모와 성장(2019-2024년)
• 세계의 차세대 면역 치료 시장 예측 : 규모와 성장(2024-2029년, 2034년)
• 세계의 차세대 면역 치료 총 시장 규모(TAM)

제6장 시장 세분화

• 세계의 차세대 면역 치료 시장 : 약물 클래스별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 단일클론항체
• 항체 약물 복합체(ADC)
• 안지오텐신 전환효소(ACE) 억제제
• 면역 체크포인트 억제제
• 세계의 차세대 면역 치료 시장 : 투여 경로별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 정맥 내
• 비경구
• 종양 내
• 피하
• 경구
• 세계의 차세대 면역 치료 시장 : 유통 채널별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 병원 약국
• 임상 약국
• 기타 유통 채널
• 세계의 차세대 면역 치료 시장 : 단일클론항체 유형별 세분화, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 항PD-1 항체
• 항PD-L1 항체
• 항CTLA-4 항체
• 항CD20 항체
• 기타 단일클론항체
• 세계의 차세대 면역 치료 시장 : 항체 약물 복합체(ADC) 유형별 세분화, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• HER2 타겟 ADC
• CD30 표적 ADC
• CD19 표적 ADC
• 기타 ADC
• 세계의 차세대 면역 치료 시장 : 안지오텐신 전환효소(ACE) 억제제 유형별 세분화, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 암 치료를 위한 ACE 억제제
• 기타 적응증에 대한 ACE 억제제
• 세계의 차세대 면역 치료 시장 : 면역 체크포인트 억제제 유형별 세분화, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• PD-1 또는 PD-L1 억제제
• CTLA-4 억제제
• 기타 면역 체크포인트 억제제

제7장 지역별 및 국가별 분석

• 세계의 차세대 면역 치료 시장 : 지역별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 세계의 차세대 면역 치료 시장 : 국가별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

• 차세대 면역 치료 시장 : 경쟁 구도
• 차세대 면역 치료 시장 : 기업 프로파일
  • Pfizer Inc. 개요, 제품 및 서비스, 전략 및 재무 분석
  • F. Hoffmann-La Roche Ltd. 개요, 제품 및 서비스, 전략 및 재무 분석
  • Merck & Co. Inc. 개요, 제품 및 서비스, 전략 및 재무 분석
  • AbbVie Inc. 개요, 제품 및 서비스, 전략 및 재무 분석
  • Sanofi SA 개요, 제품 및 서비스, 전략 및 재무 분석

제31장 기타 주요 기업 및 혁신 기업

• Bristol-Myers Squibb Company
• AstraZeneca PLC
• Novartis AG
• GlaxoSmithKline plc(GSK)
• Eli Lilly and Company
• Gilead Sciences Inc.
• Amgen Inc.
• Boehringer Ingelheim International GmbH
• Regeneron Pharmaceuticals Inc.
• Incyte Corporation
• BioNTech SE
• Xencor Inc.
• Fate Therapeutics Inc.
• Immatics NV
• Atara Biotherapeutics Inc.

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

• 차세대 면역 치료 시장(2029년) : 새로운 기회를 제공하는 국가
• 차세대 면역 치료 시장(2029년) : 새로운 기회를 제공하는 부문
• 차세대 면역 치료 시장(2029년) : 성장 전략
  • 시장 동향에 기초한 전략
  • 경쟁 전략

제36장 부록

HBR

영문 목차

영문목차

Next-generation immunotherapies are advanced treatments designed to enhance the body's immune system to combat diseases, particularly cancer, with greater precision, efficacy, and safety. These therapies surpass traditional immune-based treatments by utilizing cutting-edge technologies to overcome previous limitations, minimize side effects, and provide long-lasting immune responses.

The primary drug classes in next-generation immunotherapies include monoclonal antibodies, antibody-drug conjugates (ADCs), angiotensin-converting enzyme (ACE) inhibitors, and immune checkpoint inhibitors. Monoclonal antibodies are lab-engineered proteins that precisely target specific antigens, boosting immune response and treatment effectiveness. These drugs are administered through various routes, such as intravenous, parenteral, intratumoral, subcutaneous, and oral. They are distributed through multiple channels, including hospital pharmacies, clinical pharmacies, and other distribution networks.

The next-generation immunotherapies market research report is one of a series of new reports from The Business Research Company that provides next-generation immunotherapies market statistics, including the next-generation immunotherapies industry global market size, regional shares, competitors with the next-generation immunotherapies market share, detailed next-generation immunotherapies market segments, market trends, and opportunities, and any further data you may need to thrive in the next-generation immunotherapies industry. This next-generation immunotherapies market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The next generation immunotherapies market size has grown rapidly in recent years. It will grow from $133.81 billion in 2024 to $150.54 billion in 2025 at a compound annual growth rate (CAGR) of 12.5%. The growth during the historic period can be attributed to the increasing prevalence of oncology, higher investments in research and development, rising government initiatives, increased healthcare expenditures, and the expanding range of indications for immunotherapies.

The next generation immunotherapies market size is expected to see rapid growth in the next few years. It will grow to $238.04 billion in 2029 at a compound annual growth rate (CAGR) of 12.1%. The growth during the forecast period can be attributed to the rising prevalence of cancer, increasing healthcare expenditure, growing adoption of chimeric antigen receptor (CAR) T-cell therapy, a higher burden of chronic diseases, and expanding research in next-generation drugs. Key trends in the forecast period include a shift toward combination therapies, technological advancements, innovations in therapeutic approaches, progress in personalized medicine, and enhanced regulatory support.

The growing prevalence of cancer is expected to drive the expansion of the next-generation immunotherapies market. Cancer is a group of diseases characterized by the uncontrolled growth and spread of abnormal cells within the body. Several factors contribute to the increasing incidence of cancer, including aging populations, lifestyle changes, environmental exposures, and advancements in detection methods. Next-generation immunotherapies offer advanced, targeted treatments that enhance the body's immune response to cancer, providing improved effectiveness, durability, and personalization. For example, in May 2024, the National Cancer Institute (NCI), a US-based government agency, reported that nearly 20 million new cancer cases and 9.7 million cancer-related deaths occurred globally in 2022. Projections for 2040 estimate 29.9 million new cases and 15.3 million cancer-related deaths. Consequently, the rising prevalence of cancer is fueling the growth of the next-generation immunotherapies market.

Leading companies in the next-generation immunotherapies market are focusing on the development of innovative treatments, such as CAR T-cell therapy, to address cancers, autoimmune diseases, and infectious diseases. CAR T-cell therapy is an advanced immunotherapy technique in which a patient's T cells (a type of immune cell) are genetically engineered to express chimeric antigen receptors (CARs). For instance, in January 2025, Immuneel Therapeutics Private Limited, an India-based cell and gene therapy startup, introduced Qartemi, India's first CAR T-cell therapy. This treatment targets adult B-cell non-Hodgkin lymphoma by genetically modifying a patient's immune cells to recognize and eliminate cancer cells, offering a highly effective and personalized approach. It presents new hope for patients who have not responded to conventional treatments, with the added benefit of being more cost-effective than similar international options.

In September 2023, Coherus BioSciences Inc., a US-based biopharmaceutical company, acquired Surface Oncology Inc. for an undisclosed amount. This acquisition is part of Coherus BioSciences' strategy to expand its immuno-oncology portfolio by developing novel therapies that target the tumor microenvironment to enhance cancer treatment. Surface Oncology Inc., a US-based immuno-oncology company, specializes in next-generation immunotherapies designed to modify the tumor microenvironment for improved treatment outcomes.

Major players in the next generation immunotherapies market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc (GSK), Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Boehringer Ingelheim International GmbH, Regeneron Pharmaceuticals Inc., Incyte Corporation, BioNTech SE, Xencor Inc., Fate Therapeutics Inc., Immatics N.V., Atara Biotherapeutics Inc., Menarini Group, Alpine Immune Sciences Inc., Mereo Biopharma Group plc, Immunomic Therapeutics Inc., Indaptus Therapeutics Inc.

North America was the largest region in the next-generation immunotherapies market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the Next Generation Immunotherapies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The next-generation immunotherapies market consists of revenues earned by entities providing services such as cell therapy manufacturing services, gene editing and engineering services, consulting services, diagnostic services, and distribution and logistics. The market value includes the value of related goods sold by the service provider or included within the service offering. The next-generation immunotherapies market also includes sales of CAR-T cell therapies, natural killer (NK) cell therapies, combination therapies, and checkpoint inhibitors. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Next Generation Immunotherapies Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on next generation immunotherapies market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for next generation immunotherapies ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The next generation immunotherapies market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Class: Monoclonal Antibodies; Antibody-Drug Conjugates - ADC's; Angiotensin-Converting Enzyme (ACE) Inhibitors; Immune Checkpoint Inhibitors
• 2) By Route Of Administration: Intravenous; Parenteral; Intratumoral; Subcutaneous; Oral
• 3) By Distribution Channel: Hospital Pharmacies; Clinical Pharmacies; Other Distribution channels
• Subsegments:
• 1) By Monoclonal Antibodies: Anti-PD-1 Antibodies; Anti-PD-L1 Antibodies; Anti-CTLA-4 Antibodies; Anti-CD20 Antibodies; Other Monoclonal Antibodies
• 2) By Antibody-Drug Conjugates (ADC's): HER2-targeted ADCs; CD30-targeted ADCs; CD19-targeted ADCs; Other ADCs
• 3) By Angiotensin-Converting Enzyme (ACE) Inhibitors: ACE Inhibitors For Cancer Therapy; ACE Inhibitors For Other Indications
• 4) By Immune Checkpoint Inhibitors: PD-1 Or PD-L1 Inhibitors; CTLA-4 Inhibitors; Other Immune Checkpoint Inhibitors
• Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche Ltd.; Merck & Co. Inc.; AbbVie Inc.; Sanofi S.A.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Next Generation Immunotherapies Market Characteristics

3. Next Generation Immunotherapies Market Trends And Strategies

4. Next Generation Immunotherapies Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Next Generation Immunotherapies Growth Analysis And Strategic Analysis Framework

• 5.1. Global Next Generation Immunotherapies PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Next Generation Immunotherapies Market Growth Rate Analysis
• 5.4. Global Next Generation Immunotherapies Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Next Generation Immunotherapies Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Next Generation Immunotherapies Total Addressable Market (TAM)

6. Next Generation Immunotherapies Market Segmentation

• 6.1. Global Next Generation Immunotherapies Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Monoclonal Antibodies
• Antibody-Drug Conjugates - ADC's
• Angiotensin-Converting Enzyme (ACE) Inhibitors
• Immune Checkpoint Inhibitors
• 6.2. Global Next Generation Immunotherapies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Intravenous
• Parenteral
• Intratumoral
• Subcutaneous
• Oral
• 6.3. Global Next Generation Immunotherapies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Clinical Pharmacies
• Other Distribution channels
• 6.4. Global Next Generation Immunotherapies Market, Sub-Segmentation Of Monoclonal Antibodies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Anti-PD-1 Antibodies
• Anti-PD-L1 Antibodies
• Anti-CTLA-4 Antibodies
• Anti-CD20 Antibodies
• Other Monoclonal Antibodies
• 6.5. Global Next Generation Immunotherapies Market, Sub-Segmentation Of Antibody-Drug Conjugates (ADC's), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• HER2-targeted ADCs
• CD30-targeted ADCs
• CD19-targeted ADCs
• Other ADCs
• 6.6. Global Next Generation Immunotherapies Market, Sub-Segmentation Of Angiotensin-Converting Enzyme (ACE) Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• ACE Inhibitors For Cancer Therapy
• ACE Inhibitors For Other Indications
• 6.7. Global Next Generation Immunotherapies Market, Sub-Segmentation Of Immune Checkpoint Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• PD-1 Or PD-L1 Inhibitors
• CTLA-4 Inhibitors
• Other Immune Checkpoint Inhibitors

7. Next Generation Immunotherapies Market Regional And Country Analysis

• 7.1. Global Next Generation Immunotherapies Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Next Generation Immunotherapies Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Next Generation Immunotherapies Market

• 8.1. Asia-Pacific Next Generation Immunotherapies Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Next Generation Immunotherapies Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Next Generation Immunotherapies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Next Generation Immunotherapies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Next Generation Immunotherapies Market

• 9.1. China Next Generation Immunotherapies Market Overview
• 9.2. China Next Generation Immunotherapies Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Next Generation Immunotherapies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Next Generation Immunotherapies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Next Generation Immunotherapies Market

• 10.1. India Next Generation Immunotherapies Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Next Generation Immunotherapies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Next Generation Immunotherapies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Next Generation Immunotherapies Market

• 11.1. Japan Next Generation Immunotherapies Market Overview
• 11.2. Japan Next Generation Immunotherapies Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Next Generation Immunotherapies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Next Generation Immunotherapies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Next Generation Immunotherapies Market

• 12.1. Australia Next Generation Immunotherapies Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Next Generation Immunotherapies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Next Generation Immunotherapies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Next Generation Immunotherapies Market

• 13.1. Indonesia Next Generation Immunotherapies Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Next Generation Immunotherapies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Next Generation Immunotherapies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Next Generation Immunotherapies Market

• 14.1. South Korea Next Generation Immunotherapies Market Overview
• 14.2. South Korea Next Generation Immunotherapies Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Next Generation Immunotherapies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Next Generation Immunotherapies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Next Generation Immunotherapies Market

• 15.1. Western Europe Next Generation Immunotherapies Market Overview
• 15.2. Western Europe Next Generation Immunotherapies Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Next Generation Immunotherapies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Next Generation Immunotherapies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Next Generation Immunotherapies Market

• 16.1. UK Next Generation Immunotherapies Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Next Generation Immunotherapies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Next Generation Immunotherapies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Next Generation Immunotherapies Market

• 17.1. Germany Next Generation Immunotherapies Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Next Generation Immunotherapies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Next Generation Immunotherapies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Next Generation Immunotherapies Market

• 18.1. France Next Generation Immunotherapies Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Next Generation Immunotherapies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Next Generation Immunotherapies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Next Generation Immunotherapies Market

• 19.1. Italy Next Generation Immunotherapies Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Next Generation Immunotherapies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Next Generation Immunotherapies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Next Generation Immunotherapies Market

• 20.1. Spain Next Generation Immunotherapies Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Next Generation Immunotherapies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Next Generation Immunotherapies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Next Generation Immunotherapies Market

• 21.1. Eastern Europe Next Generation Immunotherapies Market Overview
• 21.2. Eastern Europe Next Generation Immunotherapies Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Next Generation Immunotherapies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Next Generation Immunotherapies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Next Generation Immunotherapies Market

• 22.1. Russia Next Generation Immunotherapies Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Next Generation Immunotherapies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Next Generation Immunotherapies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Next Generation Immunotherapies Market

• 23.1. North America Next Generation Immunotherapies Market Overview
• 23.2. North America Next Generation Immunotherapies Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Next Generation Immunotherapies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Next Generation Immunotherapies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Next Generation Immunotherapies Market

• 24.1. USA Next Generation Immunotherapies Market Overview
• 24.2. USA Next Generation Immunotherapies Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Next Generation Immunotherapies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Next Generation Immunotherapies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Next Generation Immunotherapies Market

• 25.1. Canada Next Generation Immunotherapies Market Overview
• 25.2. Canada Next Generation Immunotherapies Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Next Generation Immunotherapies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Next Generation Immunotherapies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Next Generation Immunotherapies Market

• 26.1. South America Next Generation Immunotherapies Market Overview
• 26.2. South America Next Generation Immunotherapies Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Next Generation Immunotherapies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Next Generation Immunotherapies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Next Generation Immunotherapies Market

• 27.1. Brazil Next Generation Immunotherapies Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Next Generation Immunotherapies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Next Generation Immunotherapies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Next Generation Immunotherapies Market

• 28.1. Middle East Next Generation Immunotherapies Market Overview
• 28.2. Middle East Next Generation Immunotherapies Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Next Generation Immunotherapies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Next Generation Immunotherapies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Next Generation Immunotherapies Market

• 29.1. Africa Next Generation Immunotherapies Market Overview
• 29.2. Africa Next Generation Immunotherapies Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Next Generation Immunotherapies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Next Generation Immunotherapies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Next Generation Immunotherapies Market Competitive Landscape And Company Profiles

• 30.1. Next Generation Immunotherapies Market Competitive Landscape
• 30.2. Next Generation Immunotherapies Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis

31. Next Generation Immunotherapies Market Other Major And Innovative Companies

• 31.1. Bristol-Myers Squibb Company
• 31.2. AstraZeneca PLC
• 31.3. Novartis AG
• 31.4. GlaxoSmithKline plc (GSK)
• 31.5. Eli Lilly and Company
• 31.6. Gilead Sciences Inc.
• 31.7. Amgen Inc.
• 31.8. Boehringer Ingelheim International GmbH
• 31.9. Regeneron Pharmaceuticals Inc.
• 31.10. Incyte Corporation
• 31.11. BioNTech SE
• 31.12. Xencor Inc.
• 31.13. Fate Therapeutics Inc.
• 31.14. Immatics N.V.
• 31.15. Atara Biotherapeutics Inc.

32. Global Next Generation Immunotherapies Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Next Generation Immunotherapies Market

34. Recent Developments In The Next Generation Immunotherapies Market

35. Next Generation Immunotherapies Market High Potential Countries, Segments and Strategies

• 35.1 Next Generation Immunotherapies Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Next Generation Immunotherapies Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Next Generation Immunotherapies Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer

관련자료